The new diagnostic test will help in guiding appropriate treatment selection for TScan’s solid tumour clinical trial. Credit: Tatiana from Pixabay.

Tempus has entered a collaboration with TScan Therapeutics for the development of a new companion diagnostic (CDx) test.

The partnership helps TScan in implementing its screening protocol for a Phase I clinical trial on solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This trial is designed for the administering of customised mixtures of TCR-Ts to patients based on tumour antigen positivity and intact HLA expression.

As part of the collaboration, Tempus’ 648-gene panel, xT assay, will be used for prospectively detecting patients with HLA loss in the tumour to select TCR-Ts, which recognise HLA genes still intact in the tumour of patients.

TScan intends to recruit individuals with solid tumours, including non-small cell lung cancer, melanoma, head and neck cancer, ovarian cancer and cervical cancer, in the trial.

TScan chief medical officer Debora Barton said: “Utilising the assay developed in collaboration with Tempus will help determine if the clinical trial participants’ tumours have undergone partial HLA loss and so will enable us to choose the most appropriate TCR-Ts that are customised for the patient’s tumour antigens and preserved HLA genes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tempus executive vice-president Michael Yasiejko said: “This CDx work is unique because we’re looking for information that’s not currently in the list of readouts you typically receive from next-generation sequencing of a solid tumour.”

Earlier this year in May, Tempus obtained premarket approval from the US Food and Drug Administration for its qualitative next-generation sequencing-based in vitro diagnostic device, xT CDx.